AEterna Zentaris to sell in-vitro fertilization drug in Japan

By Elaine Rigoli

Tampa, Fla., Sept. 21 - AEterna Zentaris, Inc. said Cetrotide (cetrorelix) has been launched in Japan for in-vitro fertilization.

Cetrotide is being manufactured and marketed in Japan by partners Nippon Kayaku Co., Ltd. and Shionogi & Co., Ltd.

The Quebec City-based global biopharmaceutical company will receive revenue from the supply of Cetrotide to its Japanese partners.

Cetrotide gained market approval for in-vitro fertilization in Japan in April, according to a company news release.

Cetrotide has been marketed worldwide (except Japan) by Serono SA since 1999, providing AEterna Zentaris with annual revenue of more than $20 million per year.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.